chimeric a10 fab fragments

Chimeric A10 Fab fragments are engineered antibody fragments that combine variable domains from different species (commonly mouse-human chimeras) and specifically recognize the A10 antigen (e.g., carbonic anhydrase XII or other A10 antigens depending on context). Fab fragments represent the antigen-binding region (fragment antigen-binding) of the antibody and are used in therapeutic or diagnostic settings due to their smaller size, which allows for deeper tissue penetration and more rapid systemic clearance compared to whole antibodies. Chimeric Fab fragments omit the Fc region, reducing effector immune function and immunogenicity. They can be produced recombinantly in bacterial systems to yield active, soluble fragments for preclinical or clinical uses[3][4][9][10]. The term "chimeric" here refers to the fusion of mouse and human antibody domains to exploit higher affinity and lower immunogenicity[4][10]. Chimeric A10 Fab fragments have been radio-labeled for targeted radionuclide therapy in animal models of cancer (for example, pancreatic cancer), where they showed tumor-specific localization and therapeutic benefit by delivering cytotoxic payloads directly to A10-expressing tumor cells[6].